Interestingly, ESCC patients with different CD22 expression levels had statistically significant differences in lymph node metastasis (p < 0.05, p = 0.008), suggesting that CD22 may promote cancer cell lymph node infiltration. Here, CD22 is linked to esophageal squamous cell carcinoma.